We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
KV Pharmaceutical has a clearer path to resume sales after it and the FDA agreed to a consent decree that allows the company to resume production operations once its facilities are deemed compliant with current good manufacturing practices (cGMP).